Overview

Tarlatamab-dlle is a novel, bispecific T-cell engaging antibody (BiTE) designed to treat specific types of advanced lung cancer. This breakthrough Immunotherapy functions as a Targeted Therapy by bridging the body’s immune cells to tumor cells for selective destruction.

Generic Name: Tarlatamab-dlle
US Brand Names: Imdelltra®
Drug Class: Bispecific T-cell Engager (BiTE) Antibody; Immunotherapy; Targeted Therapy
Route of Administration: Intravenous (IV) Infusion
FDA Approval Status: Approved

Discover vital facts about tarlatamab-dlle. Read our best, proven guide to learn safe uses, critical benefits, and strong care strategies.

Mechanism of Action

Tarlatamab-dlle is a bispecific antibody engineered to target two distinct molecules simultaneously, physically linking the immune system to the tumor.

Dual Molecular Targets: The drug possesses two binding domains:
- Anti-DLL3 Domain: Binds to Delta-like Ligand 3 (DLL3), a transmembrane protein highly expressed on the surface of Small Cell Lung Cancer (SCLC) cells, particularly those with high-grade neuroendocrine features, but minimally expressed on healthy tissues.
- Anti-CD3 Effector Domain: Binds to the CD3 receptor complex found on the surface of cytotoxic T-lymphocytes (T-cells).
Immune Cell Redirection and Activation: Tarlatamab acts as a bridge, bringing the T-cell into close proximity with the DLL3-expressing SCLC tumor cell.
T-cell Activation and Cytotoxicity: The simultaneous engagement of the CD3 receptor triggers T-cell activation, leading to the proliferation of T-cells and the directional release of cytotoxic molecules (perforin and granzyme). This process results in the highly specific killing (lysis) of the SCLC tumor cell.

FDA Approved Clinical Indications

Oncological Uses:
- Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
Non-oncological Uses:
- None currently approved.

Dosage and Administration Protocols

Tarlatamab-dlle is administered via intravenous infusion and utilizes a step-up dosing schedule to minimize the risk and severity of Cytokine Release Syndrome (CRS).

Treatment Phase	Dose	Frequency	Infusion Time	Dose Adjustments
Step-Up Dose 1	0.2 mg	Day 1 (Cycle 1)	1 hour	Renal/Hepatic: No specific dose adjustments are provided for mild-to-moderate renal or hepatic impairment. Monitor closely in severe cases.
Step-Up Dose 2	1 mg	Day 8 (Cycle 1)	1 hour	Dose Modifications: Dosing may be temporarily interrupted or discontinued for severe CRS, neurological toxicity, or other Grade 3 or higher non-hematologic toxicities.
Full Treatment Dose	10 mg	Every 2 Weeks (Day 15 of Cycle 1, then Day 1 of subsequent cycles)	1 hour	Subsequent cycles are 21 days (3 weeks).

Clinical Efficacy and Research Results

Clinical efficacy data stems from the Phase 2 DeLLphi-301 study (2020-2025 context), which supported its accelerated FDA approval.

Overall Response Rate (ORR): In heavily pre-treated patients with ES-SCLC, the ORR for the recommended dose was approximately 40%.
Duration of Response (DOR): Responses were durable, with a median Duration of Response (DOR) for the 10mg cohort reported to be around 9.7 months. This duration is highly significant in the refractory SCLC setting, which typically has a very poor prognosis.
Overall Survival (OS): While long-term OS data are maturing, the median OS observed was approximately 14.3 months in the 10 mg cohort, suggesting a substantial survival benefit compared to historical controls in this patient population.

Safety Profile and Side Effects

Black Box Warning

Cytokine Release Syndrome (CRS) and Neurologic Toxicity (including ICANS): Tarlatamab-dlle can cause severe or life-threatening CRS and fatal or life-threatening neurological toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Patients must be hospitalized and closely monitored for at least 48 hours after administration of the Step-Up Doses and the first Full Treatment Dose.

Common Side Effects (>10%)

Immune/Systemic (CRS-related): Cytokine Release Syndrome (CRS) (up to 50%), fatigue, pyrexia (fever), edema.
Gastrointestinal: Constipation, decreased appetite, nausea, diarrhea.
Neurologic: Headache, tremor, confusional state, dizziness.
Laboratory Abnormalities: Decreased lymphocyte count, increased creatinine, and increased liver enzymes (AST/ALT).

Serious Adverse Events

CRS and ICANS: Severe (Grade 3/4) CRS requires urgent management, often with corticosteroids and/or tocilizumab. ICANS symptoms can range from cognitive changes to seizures and require specialized neurological management.
Infections: Serious and fatal infections, including pneumonia and sepsis, have occurred.
Hepatotoxicity: Liver injury has been reported, requiring monitoring of LFTs.

Management Strategies:

CRS Management: Grade 1 CRS is typically managed with supportive care. Grade ≥2 CRS requires temporary withholding of Tarlatamab and treatment with corticosteroids and potentially tocilizumab.
Neurological Toxicity: Prompt evaluation is mandatory. For ICANS, treatment often involves withholding Tarlatamab and administering corticosteroids.

Research Areas

Tarlatamab is a leading agent in the development of T-cell redirecting therapies for solid tumors.

Combination Strategies: Research is exploring combining Tarlatamab with other immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) to potentially enhance the depth and duration of responses by overcoming the immune-suppressive microenvironment of SCLC.
Biomarker Expansion: Investigations are underway to evaluate Tarlatamab’s effectiveness in other neuroendocrine-type tumors and small cell variants of other cancers that also express the DLL3 target.

Patient Management and Practical Recommendations

Pre-treatment Tests to Be Performed

Labs: Baseline Complete Blood Count (CBC) with differential, Liver Function Tests (LFTs), and serum creatinine.
Neurological Assessment: Baseline neurological status evaluation prior to the first dose.

Precautions During Treatment

Mandatory Monitoring: Patients require mandatory 48-hour monitoring in a hospital or specialized facility following initial doses due to the risk of CRS and ICANS.
Infection Prophylaxis: Prophylactic antibiotics may be considered for high-risk patients.
Co-medications: Avoid concomitant use of central nervous system depressants during the initial treatment phase.

Do’s and Don’ts

DO: Immediately report any fever, chills, dizziness, severe headache, confusion, or difficulty speaking to the healthcare team.
DO: Carry a card identifying you are receiving Tarlatamab-dlle, especially when traveling.
DO: Attend all scheduled lab tests, as frequent monitoring of blood counts and organ function is essential.
DON’T: Drive or operate heavy machinery if you experience any changes in your memory, cognition, or alertness.
DON’T: Skip or delay scheduled infusions without the explicit instruction of your treating oncologist.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It summarizes medical and clinical data pertaining to tarlatamab-dlle. It does not constitute and should not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always consult with a qualified oncologist or healthcare professional regarding specific medical guidance.